in vivo and in vitro exposure of the myocardium to 14-c-bretylium showed that this drug is concentrated in cardiac ventricle and that this concentrating ability of the heart may be responsible for attaining effective antiarrhythmic concentrations in the myocardium at low plasma concentrations of the drug .
C0018827
cardiac ventricle
C0018787
heart